Inflammation and Immunology
Areas of Partnering Interest
- Autoimmune diseases: Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis
- Novel treatments for these diseases (small molecule or biotherapeutics)
- New targets and pathways in inflammation and immunology
- Lead chemical matter for targets of interest
- Next generation kinase inhibitors (i.e., noncompetitive inhibitors)
- Identifying and recruiting patients
- Understanding patient populations and matching them to appropriate therapies
- Surrogate markers for clinical trials predictive of clinical outcome
- Tissue samples which follow the course of disease
Richard Griffiths
Submit your idea
"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."
—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2009 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
